Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma

DISEASE CHARACTERISTICS: * Histologically confirmed malignancy, including, but not limited to, any of the following: * Renal cell carcinoma * Melanoma * Kaposi's sarcoma * Breast, prostate, colorectal, or lung adenocarcinoma * Bone and soft tissue sarcomas * Lymphoma * Myeloma * Tumors of neuroendocrine and endothelial cell origin * Stage IV disease * Refractory disease, resistant to established treatments, or no effective treatment available * Measurable or evaluable disease * CNS metastases allowed if no prior definitive therapy within the past 3 months and no glucocorticoids required PATIENT CHARACTERISTICS: * ECOG performance status 0-1 * Granulocyte count \> 1,500/mm\^3 * Platelet count \> 100,000/mm\^3 * Creatinine \< 1.0 times upper limit of normal (ULN) * Creatinine clearance ≥ 60 mL/min * Bilirubin \< 1.5 times ULN * AST/ALT \< 1.5 times ULN * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after completion of study treatment * No history of any of the following: * Atrial fibrillation, atrial flutter, or other serious arrhythmia (excluding asymptomatic atrial and ventricular premature complexes) * Congestive heart failure currently requiring treatment * Angina pectoris * Other severe cardiovascular disease (i.e., New York Heart Association class III or IV heart disease) * No baseline ECG abnormalities suggestive of cardiac conduction delay, i.e., 1° or greater atrio-ventricular block and/or complete or incomplete (QRS \> 120 ms) bundle branch block, or repolarization abnormalities (i.e., QTc ≥ 0.48 sec) * No systemic infections requiring antibiotics within the past 14 days * No known hepatitis B surface antigen positivity * Psychologically prepared to participate in study treatment PRIOR CONCURRENT THERAPY: * See Disease Characteristics * At least 4 weeks since prior interferon (IFN) therapy and/or ≤ 400 million units of IFN * At least 3 weeks since prior major surgery * At least 3 weeks since prior radiation therapy or chemotherapy * No prior solid organ allografts or allogeneic bone marrow transplantation * No concurrent daily glucocorticoids except for physiological replacement * No other concurrent medications known to prolong QT interval